Moxifloxacin in situ gelling microparticles-bioadhesive delivery system

Qiongyu Guo, Ahmed Aly, Oliver D Schein, Morgana M. Trexler, Jennifer Hartt Elisseeff

Research output: Contribution to journalArticle

Abstract

Antibiotic use for ocular treatments has been largely limited by poor local bioavailability with conventional eyedrops formulations. Here, we developed a controlled delivery system composed of moxifloxacin-loaded poly(lactic-co-glycolic acid) (PLGA) microparticles encapsulated in a chondroitin sulfate-based, two-component bioadhesive hydrogel. Using a simple and fast electrohydrodynamic spray drying (electrospraying) technique, surfactant-free moxifloxacin-loaded microparticles were fabricated with diameters on the order of 1 μm. A mixed solvent system of methanol/dichloromethane (MeOH/DCM) was employed to prepare the microparticles for the electrospraying processing. Extended release of moxifloxacin using a series of MeOH/DCM mixed solvents was accomplished over 10 days with release concentrations higher than the minimum inhibitory concentration (MIC). In contrast, moxifloxacin loaded directly in hydrogels was released rapidly within 24 h. We observed a decrease of the drug release rate from the microparticles when using an increased percentage of methanol in the mixed solvent from 10% to 30% (v/v), which can be explained by the mixed solvent system providing a driving force to form a gradient of the drug concentrations inside the microparticles. In addition, the delivery system developed in this study, which incorporates a bioadhesive to localize drug release by in situ gelling, may potentially integrate antibiotic prophylaxis and wound healing in the eye.

Original languageEnglish (US)
Pages (from-to)66-71
Number of pages6
JournalResults in Pharma Sciences
Volume2
Issue number1
DOIs
StatePublished - 2012

Fingerprint

Methanol
Hydrogels
Antibiotic Prophylaxis
Chondroitin Sulfates
Ophthalmic Solutions
Hydrogel
Methylene Chloride
Microbial Sensitivity Tests
Surface-Active Agents
Wound Healing
Biological Availability
Anti-Bacterial Agents
moxifloxacin
Pharmaceutical Preparations
Drug Liberation
Therapeutics
polylactic acid-polyglycolic acid copolymer

Keywords

  • Bioadhesive
  • Electrospraying
  • Microparticle
  • Moxifloxacin
  • Ophthalmic release

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Moxifloxacin in situ gelling microparticles-bioadhesive delivery system. / Guo, Qiongyu; Aly, Ahmed; Schein, Oliver D; Trexler, Morgana M.; Elisseeff, Jennifer Hartt.

In: Results in Pharma Sciences, Vol. 2, No. 1, 2012, p. 66-71.

Research output: Contribution to journalArticle

@article{26ab12ad2ace428b9d19665a6b555076,
title = "Moxifloxacin in situ gelling microparticles-bioadhesive delivery system",
abstract = "Antibiotic use for ocular treatments has been largely limited by poor local bioavailability with conventional eyedrops formulations. Here, we developed a controlled delivery system composed of moxifloxacin-loaded poly(lactic-co-glycolic acid) (PLGA) microparticles encapsulated in a chondroitin sulfate-based, two-component bioadhesive hydrogel. Using a simple and fast electrohydrodynamic spray drying (electrospraying) technique, surfactant-free moxifloxacin-loaded microparticles were fabricated with diameters on the order of 1 μm. A mixed solvent system of methanol/dichloromethane (MeOH/DCM) was employed to prepare the microparticles for the electrospraying processing. Extended release of moxifloxacin using a series of MeOH/DCM mixed solvents was accomplished over 10 days with release concentrations higher than the minimum inhibitory concentration (MIC). In contrast, moxifloxacin loaded directly in hydrogels was released rapidly within 24 h. We observed a decrease of the drug release rate from the microparticles when using an increased percentage of methanol in the mixed solvent from 10{\%} to 30{\%} (v/v), which can be explained by the mixed solvent system providing a driving force to form a gradient of the drug concentrations inside the microparticles. In addition, the delivery system developed in this study, which incorporates a bioadhesive to localize drug release by in situ gelling, may potentially integrate antibiotic prophylaxis and wound healing in the eye.",
keywords = "Bioadhesive, Electrospraying, Microparticle, Moxifloxacin, Ophthalmic release",
author = "Qiongyu Guo and Ahmed Aly and Schein, {Oliver D} and Trexler, {Morgana M.} and Elisseeff, {Jennifer Hartt}",
year = "2012",
doi = "10.1016/j.rinphs.2012.09.002",
language = "English (US)",
volume = "2",
pages = "66--71",
journal = "Results in Pharma Sciences",
issn = "2211-2863",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Moxifloxacin in situ gelling microparticles-bioadhesive delivery system

AU - Guo, Qiongyu

AU - Aly, Ahmed

AU - Schein, Oliver D

AU - Trexler, Morgana M.

AU - Elisseeff, Jennifer Hartt

PY - 2012

Y1 - 2012

N2 - Antibiotic use for ocular treatments has been largely limited by poor local bioavailability with conventional eyedrops formulations. Here, we developed a controlled delivery system composed of moxifloxacin-loaded poly(lactic-co-glycolic acid) (PLGA) microparticles encapsulated in a chondroitin sulfate-based, two-component bioadhesive hydrogel. Using a simple and fast electrohydrodynamic spray drying (electrospraying) technique, surfactant-free moxifloxacin-loaded microparticles were fabricated with diameters on the order of 1 μm. A mixed solvent system of methanol/dichloromethane (MeOH/DCM) was employed to prepare the microparticles for the electrospraying processing. Extended release of moxifloxacin using a series of MeOH/DCM mixed solvents was accomplished over 10 days with release concentrations higher than the minimum inhibitory concentration (MIC). In contrast, moxifloxacin loaded directly in hydrogels was released rapidly within 24 h. We observed a decrease of the drug release rate from the microparticles when using an increased percentage of methanol in the mixed solvent from 10% to 30% (v/v), which can be explained by the mixed solvent system providing a driving force to form a gradient of the drug concentrations inside the microparticles. In addition, the delivery system developed in this study, which incorporates a bioadhesive to localize drug release by in situ gelling, may potentially integrate antibiotic prophylaxis and wound healing in the eye.

AB - Antibiotic use for ocular treatments has been largely limited by poor local bioavailability with conventional eyedrops formulations. Here, we developed a controlled delivery system composed of moxifloxacin-loaded poly(lactic-co-glycolic acid) (PLGA) microparticles encapsulated in a chondroitin sulfate-based, two-component bioadhesive hydrogel. Using a simple and fast electrohydrodynamic spray drying (electrospraying) technique, surfactant-free moxifloxacin-loaded microparticles were fabricated with diameters on the order of 1 μm. A mixed solvent system of methanol/dichloromethane (MeOH/DCM) was employed to prepare the microparticles for the electrospraying processing. Extended release of moxifloxacin using a series of MeOH/DCM mixed solvents was accomplished over 10 days with release concentrations higher than the minimum inhibitory concentration (MIC). In contrast, moxifloxacin loaded directly in hydrogels was released rapidly within 24 h. We observed a decrease of the drug release rate from the microparticles when using an increased percentage of methanol in the mixed solvent from 10% to 30% (v/v), which can be explained by the mixed solvent system providing a driving force to form a gradient of the drug concentrations inside the microparticles. In addition, the delivery system developed in this study, which incorporates a bioadhesive to localize drug release by in situ gelling, may potentially integrate antibiotic prophylaxis and wound healing in the eye.

KW - Bioadhesive

KW - Electrospraying

KW - Microparticle

KW - Moxifloxacin

KW - Ophthalmic release

UR - http://www.scopus.com/inward/record.url?scp=84867481135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867481135&partnerID=8YFLogxK

U2 - 10.1016/j.rinphs.2012.09.002

DO - 10.1016/j.rinphs.2012.09.002

M3 - Article

C2 - 25755996

AN - SCOPUS:84867481135

VL - 2

SP - 66

EP - 71

JO - Results in Pharma Sciences

JF - Results in Pharma Sciences

SN - 2211-2863

IS - 1

ER -